dullary myeloid tumour without significant bone marrow involvement, preceding myelodysplastic syndrome or therapyrelated AML. A total of 525 patients fulfilled the inclusion criteria. Among these, 489 were younger than 15 years at the time of diagnosis and 36 were 15-18 years old. The patients were diagnosed in 21 hospitals in Denmark (n = 114), Finland (n = 97), Iceland (n = 6), Norway (n = 106) and Sweden (n = 202). Allogeneic transplants were performed in eight centres.
The Nordic AML database contains information about the time and cause of death, and 10 children who died before starting treatment, and 78 who died from treatment-related complications were identified. Information about patients registered as dying from treatment-related complications in second or third complete remission is not reported. Additional data concerning the remaining 70 patients were collected by reviewing each patient's file using a specific registration form. The files of 29 patients registered as non-responders were reviewed to verify the correctness of the data. Leukaemiarelated data, such as white blood cell count (WBC), platelet count and presence of central nervous system (CNS) leukaemia at diagnosis, French-American-British (FAB)-type and cytogenetics were collected from the database. Performance status at diagnosis was not available.
NOPHO-AML-84/88/93 treatment
The treatment regimens of the NOPHO-AML trials are shown in Fig 1 and the treatment elements including cumulative drug doses are summarized in Tables I and II . Details concerning patient characteristics and clinical outcome have been reported elsewhere (Lie et al, 2005) .
The NOPHO-AML-84 protocol was of moderate intensity with an induction of three courses of cytarabine, 6-thioguanine and doxorubicin followed by four consolidation courses with high-dose cytarabine. To reduce the frequency of non-response and relapse in the NOPHO-AML-88 study, etoposide and mitoxantrone were added in selected courses during induction and consolidation, and the interval between induction courses was reduced. The event-free survival rose from 29% to 41%, but the NOPHO-AML-88 protocol suffered from an unacceptably high frequency of toxic deaths during induction and in early consolidation. The NOPHO-AML-93 used the same induction blocks as the NOPHO-AML-88, but the dose intensity was modified: children with a good response after the first course were given their second course only following haematological recovery. Consolidation was identical with NOPHO-AML-88. The event-free survival at 5 years was 48% in the NOPHO-AML-93 protocol.
Intrathecal methotrexate was given on the first day of all courses.
In the NOPHO-AML-84/88/93 studies, allogeneic haematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) was recommended to all patients with a human leucocyte antigen (HLA)-matched family donor. For patients without a donor, autologous HSCT was optional in the NOPHO-AML-84, -88 and the first part of -93, and consequently, autologous HSCT was performed on a nonrandomized basis decided by the responsible physician. HSCT conditioning regimens and supportive care followed local guidelines.
Recommendations for supportive care measures in the NOPHO-AML-84/88/93 protocols included trimethoprim/ sulfamethoxazole prophylaxis for Pneumocystis jiroveci. Systemic antifungal prophylaxis and granulocyte-colony-stimulating factor (G-CSF) were not recommended. Cytoreduction prior to chemotherapy was performed at the discretion of the attending physician. All-trans-retinoic acid (ATRA) was recommended for patients with acute promyelocytic leukaemia (APL) as from 1999.
Definitions
The diagnosis of AML was established by morphological analysis of bone marrow (BM) aspirates according to the FAB and WHO classifications.
Central nervous system (CNS) involvement was defined as more than five leucocytes per microlitre in the cerebrospinal fluid (CSF) in combination with detectable leukaemic cells in the cytospin and/or presence of neurological symptoms, such as cranial nerve palsy.
Complete remission (CR) was defined according to the CALGB criteria (Cheson et al, 1990 ) with minor deviations: £5% leukaemic blasts in the BM with signs of normal haematopoiesis in the BM and with clear signs of regeneration of normal blood cell production in the peripheral blood (PB) (platelet count >80 · 10 9 /l without transfusions and neutrophil count >1AE0 · 10 9 /l), and no leukaemic cells in the PB or in the CSF. Response after induction was evaluated close to day 15; a BM blast cell count <5% was considered as good response. Non-responders (NR) included all patients surviving the first 42 d of treatment without achieving CR. Patients with CR criteria lasting <4 weeks were also classified as NR. NRs at day 42 (n = 29) were censored in the analysis of TRD.
Early death (ED) was defined as a fatal event occurring before or within the first 42 d of treatment. ED was subclassified into: (i) ED 0-14 before or during and after the first therapy course (<15 d of treatment) and (ii) ED in aplasia between days 15-42 from treatment start. This classification reflects the ED rate and its association with initial problems (hyperleucocytosis, leucostasis) or aplasia after induction therapy.
Treatment-related death (TRD) was defined as death unrelated to progressive disease occurring after day 42 of treatment start in patients who achieved CR. In this paper, only TRDs in CR1 are reported.
Hyperleucocytosis was defined as WBC ‡100 · 10 9 /l at diagnosis.
Infections were categorized as clinically, radiologically or microbiologically documented. Viral disease was registered when both relevant disease symptoms and virus were detected. Fungal infections were defined as proven invasive infection (positive histopathological findings or positive culture) (Ascioglu et al, 2002) .
Cytogenetics: Patients with t(8;21)(q22;q22), t(9;11)(p22; q23), t(15;17)(q22;q12-21), inv16(p13q22) and t(16;16)(p13; Tables I and II . Among patients who suffered ED day 0-14; 10 died before starting treatment, three during the first induction, and three after finishing the first induction course. ED day 15-42 included seven patients dying after the first induction course and eight after the second. Abbreviations: A, cytarabine; T, 6-thioguanine; Dox, doxorubicin; CR, complete remission; n, number; HA, high-dose cytarabine; E, etoposide; M, mitoxantrone; BM, bone marrow; ED, early death; TRD, treatment-related death. Patients who experienced a relapse (n = 203) or a second malignant neoplasm (n = 2) were censored at the time of this event. Patients without events were censored at the time of last follow-up. Cox proportional hazard regression analysis was performed with the composite endpoints as events and time to this as outcome measure. The following covariates were included: age at diagnosis (<2, 2-9, ‡10 years), WBC at diagnosis (<20, 20-99, ‡100 · 10 9 /l) and protocol (NOPHO-AML-84 vs. NOPHO-AML-88 or NOPHO-AML-93). For patients who underwent HSCT, a time-dependent covariate was defined as zero before, and one after the date of HSCT, and for all other patients, this time-dependent covariate was defined as zero.
A stepwise, multiregression analysis according to Cox was also performed for composite endpoints consisting of ED or TRD caused by infection. The analysis was adjusted for age at diagnosis and protocol.
The P-values reported are two-tailed, and P-values <0AE05 were considered significant. The statistical analyses were performed using Stata Statistical Software, Release 10 (StataCorp 2007, College Station, TX, USA).
Results
In the Nordic countries, 13% (70/525) of children diagnosed with AML died before starting treatment or from treatmentrelated complications (Table III) . ED and TRD rose from 11% in the NOPHO-AML-84 protocol to 29% in -88 and then declined to 8% in -93. The frequency of EDs and TRDs in the first half of the protocol period compared with the second half of the protocol was 9% vs. 14% in NOPHO-AML-84 (P = 0AE5), 35% vs. 24% in NOPHO-AML-88 (P = 0AE2), and 9% vs. 8% in NOPHO-AML-93 (P = 0AE8).
The analysis was performed in February 2010 with a median follow-up of 11AE8 years (range, 2AE8-25AE1 years) for patients registered as alive.
Early death day 0-14
The main causes of ED 0-14 and characteristics of these patients are given in Table IV . The death rate was largely unchanged over time with 3%, 6% and 2% in the NOPHO-AML-84, -88 and -93 protocols, respectively (P = 0AE4 and P = 0AE05 when comparing NOPHO-AML-93 with -84 and -88, respectively). Ten (63%) patients died before protocol treatment was begun and three shortly after the first induction course. Among the 16 patients (3%) who died early, 11 (69%) died from intracranial haemorrhage, three (19%) from leucostasis and two (12%) from sepsis. Age was a risk factor for ED 0-14 : 87% (n = 14) of the patients were <2 years or ‡10 years at diagnosis (P = 0AE02). Hyperleucocytosis was also a risk factor. It was present in 75% of the ED 0-14 patients compared with 15% of the AML cases in general (P < 0AE001). FAB M4 or M5 was not a significant risk factor for ED 0-14 compared with other FAB-types (P = 0AE2). However, 55% of the patients who died from a cerebral haemorrhage had FAB types M4 or M5, vs. 38% in the AML population (P = 0AE1).
Early death day 15-42
The principal cause of death among the 15 patients (3%), who died between days 15-42, was infection (93%) ( Table V) . Four (29%) already had signs of infection at the time of their last course of chemotherapy, which was the first induction course in one case. One patient died from a gastrointestinal bleed after the second induction course.
Treatment-related death (>day 42)
TRD occurred in connection with chemotherapy in 26 (5%) patients. The main cause of death was infection (n = 22, 85%) ( Table V) . Eight (36%) of these patients had signs of infection (fever and/or respiratory symptoms) when the last course of chemotherapy before death was being administered. One patient with FAB M4 died from cerebral bleeding. Two patients died from acute respiratory distress syndrome (ARDS). A 13-year-old girl died unexpectedly 1 d after the first consolidation course. She had been complaining of chest pain, but the autopsy revealed no signs of heart disease or other causes of death.
TRD occurred in ten (7%) of 150 patients transplanted in CR1. Eight (80%) of these deaths were caused by a severe infection. One patient died from veno-occlusive disease (VOD) and another from graft-versus-host-disease (GVHD) with bronchiolitis obliterans.
Three patients, all treated with chemotherapy only, died from TRD more than 1 year after end of AML treatment.
A 13-year-old female died from cardiac failure 11 years after end of treatment. She had received a heart transplant 7 years prior to her death due to anthracycline-induced cardiomyopathy. A 17-year-old boy had candidiasis in the liver and spleen during induction. Later, liver cirrhosis with oesophageal varices developed. He died from multiorgan failure 7 years after end of treatment, following a month with symptoms of pulmonary infection. A 7-month-old girl with AML FAB M4, WBC 170 · 10 9 /l and platelets 75 · 10 9 /l presented at diagnosis with cerebral bleeding and died 12 years later as a consequence of severe brain damage.
Risk factors for ED 15-42 or TRD
Both univariate and multiple Cox regression analyses of the composite endpoints consisting of ED or TRD showed that age at diagnosis was a significant prognostic factor (Table VI) . Eighteen (13%) of 141 patients <2 years of age (P = 0AE03) and 23 (14%) of 169 patients ‡10 years (P = 0AE01) died from treatment-related complications as compared with 13 (6%) of 215 children between 2 and 9 years of age. Another risk factor was treatment according to the NOPHO-AML-88 protocol (P = 0AE01). The number of ED or TRDs was 26 (23%) in the NOPHO-AML-88 as compared with 8 (8%) and 20 (6%) in the NOPHO-AML-84 and -93, respectively. WBC 20-99 · 10 9 /l at diagnosis seemed to be a risk factor as well, though this endpoint only reached statistical significance in the multiple regression analysis (P = 0AE04). FAB M3 was a risk factor for ED or TRD in the multiple Cox regression analysis (11% vs. 5%, P = 0AE05), but only a few patients had this FAB type. Allogeneic HSCT was also associated with a slight excess risk of death from treatment-related complications (HR, 2AE0; 95% confidence interval (CI), 0AE8-4AE9; P = 0AE1). Sex, platelet count and presence of CNS leukaemia at diagnosis, cytogenetics and size of the treating department were not statistically significant risk factors.
Death in FAB M3
Eight (29%) of 28 patients with FAB type M3 suffered ED or TRD, two (25%) within the first 2 weeks of diagnosis from either a CNS bleed before starting chemotherapy or ATRA (Table IV) . The other six all died from infections. FAB M3 was not a significant risk factor compared with other FAB types for ED 0-14 (7% vs. 3%, P = 0AE2), but it was a significant risk factor for ED or TRD (11% vs. 5%, P = 0AE05). 
Cause of death
Death from infection. Infection was the main reason for ED or TRD (n = 46; 66%) (Table V) . After day 15, infection was considered the cause of death in 44 (81%) of 54 deaths. Infection was the cause of death in eight (80%) of 10 patients dying from treatment-related causes during HSCT. In 14 patients, fatal complications caused by infections occurred as a result of bacterial pathogens; a gram-positive isolate in six cases and a gram-negative isolate in eight. Pseudomonas aeruginosa (n = 7) were predominant among gram-negative pathogens, Klebsiella was isolated in a single case. The gram-positive pathogens were Streptococci (n = 2), Staphylococci (n = 2), Bacillus cereus (n = 1) and Gemella (n = 1). Eleven patients died of fungal infection. This was caused by Aspergillus in six patients, by Candida in four patients and in one case no specific microorganism could be identified. Nine (82%) of 11 cases of fungal infection were only diagnosed by autopsy. Viruses causing TRD were cytomegalovirus (n = 1) and respiratory syncytial virus (n = 1). In four cases, the infection was polybacterial or polymicrobial. Fifteen patients died of clinically/radiologically documented infections without having a pathogen identified.
Age <2 (P = 0AE02) or ‡10 years (P = 0AE01) at diagnosis were the only statistically significant risk factors for infection-related ED 15-42 or TRD (Table VII) .
Death from cardiac failure. Only one patient receiving a cumulative dose of doxorubicin of 150 mg/m 2 and mitoxantrone 60 mg/m 2 died from cardiac failure. Six patients who died from infection had cardiac insufficiency a few days preceding their death but in all cases, cardiac failure was considered part of septic shock.
Discussion
The three consecutive NOPHO-AML protocols have shown a successive improvement in outcome from a 5-year overall survival of 38% in the NOPHO-AML-84 to 64% in the NOPHO-AML-93 (Lie et al, 2005) . This analysis shows that 13% of children diagnosed with AML in the Nordic countries died before starting treatment or from treatment-related complications. The rates of ED and TRD rose from 11% in NOPHO-AML-84 to 29% in -88, but then fell to 8% in -93. A total of 88% of the patients with ED 0-14 died due to haemorrhage or leucostasis. The risk factors for death before day 15 were hyperleucocytosis, age <2 years or ‡10 years. After day 15, infection caused 81% of ED and TRDs. Risk factors were age (<2 years or ‡10 years at diagnosis), WBC 20-99 · 10 9 /l, FAB M3 and treatment according to the NOPHO-AML-88 protocol. The number of EDs and TRDs has been estimated in different AML trials as shown in Table VIII (Riley et al, 1999; Creutzig et al, 2004 Creutzig et al, , 2006 Rubnitz et al, 2004; Dluzniewska et al, 2005; Entz-Werle et al, 2005; Gibson et al, 2005; Kardos ED , early death day 15-42; TRD, treatment-related death; HR, hazard ratio; 95% CI, 95% confidence interval; HSCT, haematopoietic stem cell transplantation; CNS, central nervous system. *Adjusted for age (2-9 vs. <2 or ‡10 years), leucocytes at diagnosis (<20 vs. 20-99 or ‡100 · 10 9 /l) and protocol (NOPHO-AML-84 vs. NOPHO-AML-88 or NOPHO-AML-93). Favourable cytogenetics: t(8;21)(q22;q22), t(9;11)(p22;q23), t(15;17)(q22;q12-21), inv16(p13q22) and t(16;16)(p13;q22). ). ED occurred in 2-10% and TRD in 2-16%. The percentage was higher with a high rate of HSCT. With a 5-year overall survival of 60% or above, our ED and TRD results are similar to those reported by others (Riley et al, 1999; Creutzig et al, 2004) . Several groups have reported a decrease in toxic death rates over time without concomitant changes in therapy or even with more intensive therapy. However in the 1982-1997 period, the Dutch childhood oncology group observed that chemotherapy-related mortality (Dluzniewska et al, 2005) 1998-2002 104 0-14 8 10 50 AML99 (Tsukimoto et al, 2009) 2000-2002 240 0-18 2à 4 7 6 CCG 2891 1989-1995 750 0-14 4 15 47 DCOG AML-92/94 (Kardos et al, 2005) 1992-1998 78 0-14 10 16 50 EORTC-CLG 58921 (Entz-Werle et al, 2005) 1993-2000 166 0-14 2 6 62 LAME 91 (Perel et al, 2005) 1991-1998 247 0-14 4 6 61 MRC AML 12 (Gibson et al, 2005) 1995 Is from the paper (Creutzig et al, 2006) which included 473 patients in the period from 1998 to 2003. àPatients who died before initiation therapy were excluded (n = 3).
rose from 3% to 8% during consolidation, which was perhaps related to the scheduling of intensification blocks (Slats et al, 2005) . This illustrates the delicate balance between minor changes in treatment and the risk of treatment-related mortality. Within the different NOPHO-AML protocols, no significant reduction in the number of EDs and TRDs occurred over time in contrast to the learning curve demonstrated in the Children's Cancer Group (CCG)-2961 study (Lange et al, 2008) .
The causes of ED and TRD were similar in the different AML studies despite variations in supportive care practices (Lehrnbecher et al, 2009) . In contrast to the excess mortality rate due to cardiac causes (standardized mortality rate = 5AE0) in the Childhood Cancer Survivor Study (CCSS) (Armstrong et al, 2009) , the frequency of cardiac mortality in our population was low.
Three patients died 7-12 years after end of treatment from late effects of treatment or complications in relation to initial AML manifestations, which underlines the importance of continued long-term follow-up. In the CCSS, 4% of 272 5-year AML survivors treated without HSCT had died from other causes than relapse 8-26 years after diagnosis (Mulrooney et al, 2008) .
In the AML-BFM-93 and -98 trials, risk factors for death before day 15 were low performance status at presentation, initial CNS involvement, hyperleucocytosis and FAB M5 . After day 15, age above 10 years and FAB M0 were risk factors. Further studies are needed to determine whether pharmacokinetic differences account for the increased death rate among children <2 years and ‡10 years of age (Palle et al, 2006 (Palle et al, , 2009 . We had no data on body mass index at diagnosis, but the CCG-2961 showed that overweight and underweight children and adolescents with AML were more likely to experience treatment-related mortality (Lange et al, 2005) . The high rate of ED and TRD in APL patients in the NOPHO-AML studies may be due to the low incidence of FAB M3 in Northern Europe and therefore limited experience and late introduction of ATRA.
In the AML-BFM-78 and -83 studies, the risk of ED due to leucostasis and/or haemorrhage was significantly increased in children with FAB M5, hyperleucocytosis, and extramedullary organ involvement (Creutzig et al, 1987) . These findings are in line with the results from our studies. We also found a higher proportion of EDs from leucostasis/haemorrhage in children <2 years than in children between 2 and 9 years of age. We observed a small decline in the incidence of hyperleucocytosis over time, from 18% in the NOPHO-AML-84 and 19% in the NOPHO-AML-88 to 13% in the NOPHO-AML-93 protocol. The low number of EDs in the NOPHO-AML-84 (3%) and -93 (2%) precludes any conclusion as to whether the lower frequency of hyperleucocytosis reduced ED as shown in the study from St. Jude Children's Research Hospital (Inaba et al, 2008) .
Next to relapses, infection remains the most important cause of morbidity and mortality among children with AML.
Infections caused 85% of all EDs and TRDs when deaths before starting treatment were excluded. The infectionrelated mortality of 9% (46/525) is comparable to that reported in other recent AML studies, which quoted frequencies of 5-11% (Riley et al, 1999; Lehrnbecher et al, 2004; Brunet et al, 2006; Sung et al, 2007) . However, it is difficult to compare results and draw conclusions about trends in infection-related mortality due to the use of different definitions and underestimation of the true incidence of these infections. Our Nordic trials included a large amount of infection-related deaths where no microorganism could be identified. Like in other studies, a significant number of invasive fungal infections were diagnosed only at autopsy (Groll et al, 1996) . Risk factors for infection-related deaths in the CCG 2961 trial were underweight, non-white race and age above 16 years (Sung et al, 2007) . In our study, age <2 or ‡10 years at diagnosis were risk factors for death due to infection. NOPHO-AML-88 used the principle of timed sequential induction, which caused an unacceptable increase in ED and TRD. This is similar to the results from the CCG-2891 trial, where fatal infections were more common during intensive than during standard-timed induction .
To allow comparison between cooperative AML groups and to improve our understanding of infection outcomes, standard infection definitions should be used (Sung et al, 2008) . To reduce infection-related mortality, it is important to improve both prevention and treatment through prophylaxis, early diagnosis and aggressive management. The current NOPHO-AML 2004 protocol includes prophylactic antifungal therapy with fluconazole but no prophylactic G-CSF or anti-bacterial therapy because there is no solid evidence that these measures reduce mortality in children with AML. However, a recent study from St. Jude Children's Research Hospital reduced the odds of bacterial sepsis by 93% using intravenous vancomycin with oral ciprofloxacin or a cephalosporin (Kurt et al, 2008) . A relatively small number of patients were studied and larger multi-institutional studies are needed before recommendations on these prophylactic antibiotic regimens can be made. The development of targeted and more leukaemia-specific drugs may reduce the toxic effect on normal cells and thereby reduce infectionrelated morbidity. Identification of possible immunogenetic risk profiles at the start of therapy could potentially be helpful for risk-adapted and individualized supportive care (Hartel et al, 2007) . Initial data have demonstrated that interleukin-6 and chitotriosidase polymorphisms may modify infection risk (Lehrnbecher et al, 2005) . In a study from the CCG, polymorphisms in the gene encoding cytidin deaminase were associated with an increased risk of treatmentrelated mortality with cytarabine-based therapy for AML (Bhatla et al, 2009) .
Our study has some limitations. AML is rare in children and the relatively low number of patients therefore hampers statistical analysis of risk factors at subgroup level. Limited information in the medical records sometimes made it difficult to categorize the cause of death. In some cases, it was difficult to assess whether the patient was in CR, and to determine whether the cause of death was treatment-or disease-related.
The number of EDs and TRDs in childhood AML in the Nordic countries remains substantial. Further studies should be conducted to explore the pathogenesis behind leucostasis/ haemorrhage and prospective studies of the effect of cytoreduction should be performed. Optimal antifungal prophylaxis is essential, and studies on the benefit of antibacterial prophylaxis and individual risk factors for ED and TRD are needed.
